Celcuity Inc. recently announced the completion of its New Drug Application submission to the U.S. Food and Drug Administration for gedatolisib, targeting hormone receptor positive, HER2 negative ...

Most types of breast cancer produce similar symptoms and are discovered the same way—finding a strange new lump during a self-exam, or a healthcare provider spotting something suspicious during a ...

The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is ...

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

An interview with Dr. Beverly Moy from Massachusetts General Hospital in Boston, MA, lead author on "Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer That is Either ...

While CDK4/6 inhibitors are “liberating” for this breast cancer subset, questions remain about what to do in later lines of therapy, according to a presentation at the CURE® Educated Patient Breast ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result ...

Normally, HER2 helps your healthy breast cells grow and divide. But too much HER2 can trigger cells to grow out of control. HER2-positive breast cancer happens when the HER2 gene in your DNA mutates ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.